The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results